KOD News and Press, Kodiak Sciences Inc From 03/26/20

Market Pulse This week all the major indexes made new lows. The market continues to be under stress and this is not the final low. Biotechs were one of the few industry groups that didn't make a new low this week. A respite from non-stop selling will come from the economic stimulus package w...

PALO ALTO, Calif. , March 24, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that the company received full registration of thei...

InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...

Healthcare Pulse A new reality dawned as the stock market entered a bear market. It wasn't a tiptoe moment for the bear. The market simply plummeted into a bear market canyon. Just from March 4 to March 12, in about a week, the S&P 500 and Nasdaq declined 20% or more. The healthcare ...

Kodiak Sciences (NASDAQ: KOD ): Q4 GAAP EPS of -$0.40 misses by $0.03 . More news on: Kodiak Sciences Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

PALO ALTO, Calif. , March 16, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today reported business highlights and financial results for the fo...

InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most i...

Healthcare Pulse Source: Bloomberg The fear of Coronavirus (Covid-19) has infected the stock market. The market's patience completely ran out this week as the Coronavirus news, which has continued to weigh heavily on the negative side, sent the market reeling in a feral pullback. Wha...

PALO ALTO, Calif. , Feb. 27, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced today that management will present at the following upcomi...

Neoleukin  Therapeutics (NASDAQ: NLTX ) initiated with Buy rating and $20 (82% upside) price target at Guggenheim. More news on: Xeris Pharmaceuticals, Inc., Neoleukin Therapeutics, Inc., Amarin Corporation plc, Healthcare stocks news, Stocks on the move, , Read more ...